Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia

International Journal of Molecular Epidemiology and Genetics

Volumn 4, Issue 3, 2013, Pages 140-149

  Abbenhardt, Clare ^a   Poole, Elizabeth M ^b,c   Kulmacz, Richard J ^d   Xiao, Liren ^b   Curtin, Karen ^e   Galbraith, Rachel L ^b   Duggan, David ^f   Hsu, Li ^b   Makar, Karen W ^b   Caan, Bette J ^g   Koepl, Lisel ^b   Owen, Robert W ^a   Scherer, Dominique ^a   Carlson, Christopher S ^b   Potter, John D ^b,h,i   Slattery, Martha L ^d   Ulrich, Cornelia M ^a,b,i  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Fred Hutchinson Cancer Research Center   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^g Department of Research ^*  (United States)

^h MASSEY UNIVERSITY   (New Zealand)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Case control study; Colorectal neoplasia; Phospholipase A2G1B; Polymorphism

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2;

ADULT; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; COLORECTAL TUMOR; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84884241711     PISSN: 19481756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. GLOBOCAN. GLOBOCAN 2008 fast stats. IARC 2008.
2. Coussens LM and Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
3. Mantovani A, Marchesi F, Porta C, Sica A and Allavena P. Inflammation and cancer: breast cancer as a prototype. Breast 2007; 16: S27-33. Epub 2007 Aug 2030.
4. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294: 1871-1875.
5. Soberman RJ and Christmas P. The organization and consequences of eicosanoid signaling. J Clin Invest 2003; 111: 1107-1113.
6. Cuendet M and Pezzuto JM. The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol Drug Interact 2000; 17: 109-157.
7. Jones R, Adel-Alvarez LA, Alvarez OR, Broaddus R and Das S. Arachidonic acid and colorectal carcinogenesis. Mol Cell Biochem 2003; 253: 141-149.
8. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C and Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009; 30: 377-386.
9. Menna C, Olivieri F, Catalano A and Procopio A. Lipoxygenase inhibitors for cancer prevention: promises and risks. Curr Pharm Des 2010; 16: 725-733.
10. Asano TK and McLeod RS. Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database Syst Rev 2004; CD004079.
11. Ulrich CM, Bigler J and Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006; 6: 130-140.
12. Cathcart MC, Lysaght J and Pidgeon GP. Eicosanoid signalling pathways in the development and progression of colorectal cancer: novel approaches for prevention/intervention. Cancer Metastasis Rev 2011; 30: 363-385.
13. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT and Ogino S. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012; 367: 1596-1606.
14. Horrobin DF. Nutritional and medical importance of gamma-linolenic acid. Prog Lipid Res 1992; 31: 163-194.
15. Rimon A and Shapiro B. Properties and specificity of pancreatic phospholipase A. Biochem J 1959; 71: 620-623.
16. Barros H, Sternby B and Nilsson A. Hydrolysis of phosphatidylinositol by human pancreatic phospholipase A2. Scand J Gastroenterol 1990; 25: 134-140.
17. Dennis EA. Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem 1994; 269: 13057-13060.
18. Wang X, Baek SJ and Eling T. COX inhibitors directly alter gene expression: role in cancer prevention? Cancer Metastasis Rev 2011; 30: 641-657.
19. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337.
20. Potter JD, Bostick RM, Grandits GA, Fosdick L, Elmer P, Wood J, Grambsch P and Louis TA. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. Cancer Epidemiol Biomarkers Prev 1996; 5: 779-784.
21. Slattery ML, Potter J, Caan B, Edwards S, Coates A, Ma KN and Berry TD. Energy balance and colon cancer--beyond physical activity. Cancer Res 1997; 57: 75-80.
22. Slattery ML, Caan BJ, Benson J and Murtaugh M. Energy balance and rectal cancer: an evaluation of energy intake, energy expenditure, and body mass index. Nutr Cancer 2003; 46: 166-171.
23. Slattery ML, Curtin K, Anderson K, Ma KN, Ballard L, Edwards S, Schaffer D, Potter J, Leppert M and Samowitz WS. Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst 2000; 92: 1831-1836.
24. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M and Slattery ML. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 2000; 9: 1193-1197.
25. Samowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, Leppert MF and Slattery ML. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer 2002; 99: 597-602.
26. Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, Wolff RK and Slattery ML. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005; 129: 837-845.
27. Gauderman WJ, Murcray C, Gilliland F and Conti DV. Testing association between disease and multiple SNPs in a candidate gene. Genet Epidemiol 2007; 31: 383-395.
28. Potter JD and McMichael AJ. Large bowel cancer in women in relation to reproductive and hormonal factors: a case-control study. J Natl Cancer Inst 1983; 71: 703-709.
29. Potter JD and McMichael AJ. Diet and cancer of the colon and rectum: a case-control study. J Natl Cancer Inst 1986; 76: 557-569.
30. Yamauchi M, Lochhead P, Morikawa T, Huttenhower C, Chan AT, Giovannucci E, Fuchs C and Ogino S. Colorectal cancer: a tale of two sides or a continuum? Gut 2012; 61: 794-797.
31. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, Liao X, Waldron L, Hoshida Y, Huttenhower C, Chan AT, Giovannucci E, Fuchs C and Ogino S. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012; 61: 847-854.
32. Peters U, Jiao S, Schumacher FR, Hutter CM, Aragaki AK, Baron JA, Berndt SI, Bezieau S, Brenner H, Butterbach K, Caan BJ, Campbell PT, Carlson CS, Casey G, Chan AT, Chang-Claude J, Chanock SJ, Chen LS, Coetzee GA, Coetzee SG, Conti DV, Curtis KR, Duggan D, Edwards T, Fuchs CS, Gallinger S, Giovannucci EL, Gogarten SM, Gruber SB, Haile RW, Harrison TA, Hayes RB, Henderson BE, Hoffmeister M, Hopper JL, Hudson TJ, Hunter DJ, Jackson RD, Jee SH, Jenkins MA, Jia WH, Kolonel LN, Kooperberg C, Kury S, Lacroix AZ, Laurie CC, Laurie CA, Le Marchand L, Lemire M, Levine D, Lindor NM, Liu Y, Ma J, Makar KW, Matsuo K, Newcomb PA, Potter JD, Prentice RL, Qu C, Rohan T, Rosse SA, Schoen RE, Seminara D, Shrubsole M, Shu XO, Slattery ML, Taverna D, Thibodeau SN, Ulrich CM, White E, Xiang Y, Zanke BW, Zeng YX, Zhang B, Zheng W and Hsu L. Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. Gastroenterology 2013; 144: 799-807, e724.
33. Newcomb PA, Baron J, Cotterchio M, Gallinger S, Grove J, Haile R, Hall D, Hopper JL, Jass J, Le Marchand L, Limburg P, Lindor N, Potter JD, Templeton AS, Thibodeau S and Seminara D. Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 2331-2343.
34. Ulrich CM, Bigler J and Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006; 6: 130-140.
35. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.
36. Lambeau G and Gelb MH. Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem 2008; 77: 495-520.
37. Mounier CM, Wendum D, Greenspan E, Flejou JF, Rosenberg DW and Lambeau G. Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate. Br J Cancer 2008; 98: 587-595.
38. Wilson SG, Adam G, Langdown M, Reneland R, Braun A, Andrew T, Surdulescu GL, Norberg M, Dudbridge F, Reed PW, Sambrook PN, Kleyn PW and Spector TD. Linkage and potential association of obesity-related phenotypes with two genes on chromosome 12q24 in a female dizygous twin cohort. Eur J Hum Genet 2006; 14: 340-348.
39. Kant P and Hull MA. Excess body weight and obesity--the link with gastrointestinal and hepatobiliary cancer. Nat Rev Gastroenterol Hepatol 2011; 8: 224-238.
40. Wang D and Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010; 10: 181-193.
41. Rigas B, Goldman IS and Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122: 518-523.
42. Ogino S, Chan AT, Fuchs CS and Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011; 60: 397-411.
43. Ogino S and Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst 2010; 102: 365-367.
44. Curtin K, Slattery ML and Samowitz WS. CpG island methylation in colorectal cancer: past, present and future. Patholog Res Int 2011; 2011: 902674.
45. Spitz MR, Caporaso NE and Sellers TA. Integrative cancer epidemiology--the next generation. Cancer Discov 2012; 2: 1087-1090.